Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

George L. Mutter, M.D.

Concepts

This page shows the publications George Mutter has written about Breast Neoplasms.
Connection Strength

0.104
  1. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med. 2007 Dec 20; 357(25):2543-51.
    View in: PubMed
    Score: 0.015
  2. Fukino K, Shen L, Patocs A, Mutter GL, Eng C. Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA. 2007 May 16; 297(19):2103-11.
    View in: PubMed
    Score: 0.015
  3. Weber F, Shen L, Fukino K, Patocs A, Mutter GL, Caldes T, Eng C. Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet. 2006 Jun; 78(6):961-72.
    View in: PubMed
    Score: 0.014
  4. Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM, Plass C, Caldes T, Mutter GL, Villalona-Calero MA, Eng C. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer. 2005 May 23; 92(10):1922-6.
    View in: PubMed
    Score: 0.013
  5. Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C. Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res. 2004 Oct 15; 64(20):7231-6.
    View in: PubMed
    Score: 0.012
  6. Biswas DK, Cruz A, Pettit N, Mutter GL, Pardee AB. A therapeutic target for hormone-independent estrogen receptor-positive breast cancers. Mol Med. 2001 Jan; 7(1):59-67.
    View in: PubMed
    Score: 0.009
  7. Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, Mackay A, O'Hare MJ, Kaelin CM, Mutter GL, Pardee AB, Sager R. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res. 2000 Apr 15; 60(8):2232-8.
    View in: PubMed
    Score: 0.009
  8. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999 Oct; 155(4):1253-60.
    View in: PubMed
    Score: 0.009
  9. Ford HL, Kabingu EN, Bump EA, Mutter GL, Pardee AB. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proc Natl Acad Sci U S A. 1998 Oct 13; 95(21):12608-13.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.